An efficient, chemically-defined semisynthetic lipid-adjuvanted nanoparticulate vaccine development system

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 9, Issue 7, 2013, Pages 935-944

  Moyle, Peter M ^a   Hartas, Jon ^b   Henningham, Anna ^a   Batzloff, Michael R ^b   Good, Michael F ^b   Toth, Istvan ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b GRIFFITH UNIVERSITY   (Australia)

Author keywords

Lipid adjuvants; Recombinant proteins; Semisynthesis; Streptococcus pyogenes; Subunit vaccines

Indexed keywords

ANTIBODY PRODUCTION; NANO PARTICULATES; NANOPARTICLE SYSTEMS; PROTEIN ANTIGENS; SEMISYNTHESIS; STREPTOCOCCUS PYOGENES; SUBUNIT VACCINE; VACCINE DEVELOPMENT;

ANTIGENS; CELL MEMBRANES; LIPOPROTEINS; NANOPARTICLES; OPTIMIZATION; PEPTIDES; RECOMBINANT PROTEINS; STRAIN; VACCINES;

ANTIBODIES;

ADJUVANT; ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; LIPID; LIPOPROTEIN; M PROTEIN; NANOPARTICLE; RECOMBINANT PROTEIN; STREPTOCOCCUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; CELL SURFACE; CONTROLLED STUDY; DENDRITIC CELL; DRUG CONJUGATION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; STREPTOCOCCUS PYOGENES; VACCINATION;

MURINAE; MUS; STREPTOCOCCUS PYOGENES;

LIPID ADJUVANTS; RECOMBINANT PROTEINS; SEMISYNTHESIS; STREPTOCOCCUS PYOGENES; SUBUNIT VACCINES;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, BACTERIAL; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNITY; LIPIDS; LIPOPROTEINS; MALEIMIDES; MICE; MICE, INBRED C57BL; NANOPARTICLES; STREPTOCOCCAL INFECTIONS; STREPTOCOCCAL VACCINES; STREPTOCOCCUS PYOGENES;

EID: 84884288961     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2013.01.009     Document Type: Article

References (43)

1. Pulendran B., Ahmed R. Immunological mechanisms of vaccination. Nat Immunol 2011, 12:509-517.
2. Nossal G.J. Vaccines of the future. Vaccine 2011, 29:D111-D115.
3. Hedayat M., Takeda K., Rezaei N. Prophylactic and therapeutic implications of toll-like receptor ligands. Med Res Rev 2012, 32:294-325.
4. Gibbons W.A., Hughes R.A., Charalambous M., Christodoulou M., Szeto A., Aulabaugh A.E., et al. Lipidic peptides. 1. Synthesis, resolution and structural elucidation of lipidic amino-acids and their homo-oligomers and heterooligomers. Liebigs Ann Chem 1990, 1175-1183.
5. Moyle P.M., Toth I. Self-adjuvanting lipopeptide vaccines. Curr Med Chem 2008, 15:506-516.
6. Zaman M., Abdel-Aal A.B., Fujita Y., Ziora Z.M., Batzloff M.R., Good M.F., et al. Structure-activity relationship for the development of a self-adjuvanting mucosally active lipopeptide vaccine against Streptococcus pyogenes. J Med Chem 2012, 55:8515-8523.
7. Moyle P.M., Olive C., Ho M.F., Pandey M., Dyer J., Suhrbier A., et al. Toward the development of prophylactic and therapeutic human papillomavirus type-16 lipopeptide vaccines. J Med Chem 2007, 50:4721-4727.
8. Zaman M., Abdel-Aal A.B., Fujita Y., Phillipps K.S., Batzloff M.R., Good M.F., et al. Immunological evaluation of lipopeptide group A streptococcus (GAS) vaccine: structure-activity relationship. PLoS One 2012, 7:e30146.
9. Phillipps K.S., Wykes M.N., Liu X.Q., Brown M., Blanchfield J., Toth I. A novel synthetic adjuvant enhances dendritic cell function. Immunology 2009, 128:e582-e588.
10. Moisa A.A., Kolesanova E.F. Synthetic peptide vaccines. Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry 2011, 4:321-332.
11. Kent S.B. Total chemical synthesis of proteins. Chem Soc Rev 2009, 38:338-351.
12. Cox M.M. Recombinant protein vaccines produced in insect cells. Vaccine 2012, 30:1759-1766.
13. Zom G.G., Khan S., Filippov D.V., Ossendorp F. TLR ligand-peptide conjugate vaccines: toward clinical application. Adv Immunol 2012, 114:177-201.
14. Figueiredo R.M., Oczipka P., Frohlich R., Christmann M. Synthesis of 4-maleimidobutyric acid and related maleimides. Synthesis 2008, 1316-1318.
15. Hermanson G.T. The chemistry of reactive groups. Bioconjugate Techniques 2008, 169-212. Amsterdam, Academic Press. 2nd ed.
16. Cole J.N., Barnett T.C., Nizet V., Walker M.J. Molecular insight into invasive group A streptococcal disease. Nat Rev Microbiol 2011, 9:724-736.
17. Hayman W.A., Brandt E.R., Relf W.A., Cooper J., Saul A., Good M.F. Mapping the minimal murine T cell and B cell epitopes within a peptide vaccine candidate from the conserved region of the M protein of group A streptococcus. Int Immunol 1997, 9:1723-1733.
18. Brandt E.R., Teh T., Relf W.A., Hobb R.I., Good M.F. Protective and nonprotective epitopes from amino termini of M proteins from Australian aboriginal isolates and reference strains of group A streptococci. Infect Immun 2000, 68:6587-6594.
19. Henningham A., Chiarot E., Gillen C.M., Cole J.N., Rohde M., Fulde M., et al. Conserved anchorless surface proteins as group A streptococcal vaccine candidates. J Mol Med 2012, 90:1197-1207.
20. Bensi G., Mora M., Tuscano G., Biagini M., Chiarot E., Bombaci M., et al. Multi high-throughput approach for highly selective identification of vaccine candidates: the Group A Streptococcus case. Mol Cell Proteomics 2012, 11. [M111.015693].
21. Olive C., Ho M.F., Dyer J., Lincoln D., Barozzi N., Toth I., et al. Immunization with a tetraepitopic lipid core peptide vaccine construct induces broadly protective immune responses against group A Streptococcus. J Infect Dis 2006, 193:1666-1676.
22. Alexander J., Sidney J., Southwood S., Ruppert J., Oseroff C., Maewal A., et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1994, 1:751-761.
23. Caminschi I., Shortman K. Boosting antibody responses by targeting antigens to dendritic cells. Trends Immunol 2012, 33:71-77.
24. Curiel T.J., Morris C., Brumlik M., Landry S.J., Finstad K., Nelson A., et al. Peptides identified through phage display direct immunogenic antigen to dendritic cells. J Immunol 2004, 172:7425-7431.
25. Wu G., Wolf J.B., Ibrahim A.F., Vadasz S., Gunasinghe M., Freeland S.J. Simplified gene synthesis: a one-step approach to PCR-based gene construction. J Biotechnol 2006, 124:496-503.
26. Ross B.P., Falconer R.A., Toth I. N-1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl (N-Dde) lipoamino acids. Molbank 2008, 2:M566.
27. Moyle P.M., Olive C., Ho M.F., Good M.F., Toth I. Synthesis of a highly pure lipid core peptide based self-adjuvanting triepitopic group A streptococcal vaccine, and subsequent immunological evaluation. J Med Chem 2006, 49:6364-6370.
28. Bauer M.J., Georgousakis M.M., Vu T., Henningham A., Hofmann A., Rettel M., et al. Evaluation of novel Streptococcus pyogenes vaccine candidates incorporating multiple conserved sequences from the C-repeat region of the M-protein. Vaccine 2012, 30:2197-2205.
29. Fischetti V.A. Streptococcal M, protein: molecular design and biological behavior. Clin Microbiol Rev 1989, 2:285-314.
30. Georgousakis M.M., Hofmann A., Batzloff M.R., McMillan D.J., Sriprakash K.S. Structural optimisation of a conformational epitope improves antigenicity when expressed as a recombinant fusion protein. Vaccine 2009, 27:6799-6806.
31. Babiuk L.A. Broadening the approaches to developing more effective vaccines. Vaccine 1999, 17:1587-1595.
32. Gentle I.E., De Souza D.P., Baca M. Direct production of proteins with N-terminal cysteine for site-specific conjugation. Bioconjug Chem 2004, 15:658-663.
33. Hughes R.A., Miklos A.E., Ellington A.D. Gene synthesis: methods and applications. Methods Enzymol 2011, 498:277-309.
34. Bryksin A.V., Matsumura I. Overlap extension PCR cloning: a simple and reliable way to create recombinant plasmids. Biotechniques 2010, 48:463-465.
35. Jungbauer A., Kaar W. Current status of technical protein refolding. J Biotechnol 2007, 128:587-596.
36. Tam J.P., Wu C.R., Liu W., Zhang J.W. Disulfide bond formation in peptides by dimethyl sulfoxide. Scope and applications. J Am Chem Soc 1991, 113:6657-6662.
37. 42 structural stability and immunodominance in mice. Biotechnol J 2012, 7:133-147.
38. Magalhaes P.O., Lopes A.M., Mazzola P.G., Rangel-Yagui C., Penna T.C., Pessoa A. Methods of endotoxin removal from biological preparations: a review. J Pharm Pharm Sci 2007, 10:388-404.
39. Bachmann M.F., Jennings G.T. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 2010, 10:787-796.
40. Chapel H.M., August P.J. Report of nine cases of accidental injury to man with Freund's complete adjuvant. Clin Exp Immunol 1976, 24:538-541.
41. Mohamadzadeh M., Durmaz E., Zadeh M., Pakanati K.C., Gramarossa M., Cohran V., et al. Targeted expression of anthrax protective antigen by Lactobacillus gasseri as an anthrax vaccine. Future Microbiol 2010, 5:1289-1296.
42. Erskine C.L., Krco C.J., Hedin K.E., Borson N.D., Kalli K.R., Behrens M.D., et al. MHC class II epitope nesting modulates dendritic cell function and improves generation of antigen-specific CD4 helper T cells. J Immunol 2011, 187:316-324.
43. Vohra H., Dey N., Gupta S., Sharma A.K., Kumar R., McMillan D., et al. M protein conserved region antibodies opsonise multiple strains of Streptococcus pyogenes with sequence variations in C-repeats. Res Microbiol 2005, 156:575-582.